Israeli company ReWalk Robotics, which recently received approval from the FDA for its exoskeleton that enables paraplegics to walk, has announced its plan for a $50 IPO, with 3.4 million shares at a price range of $14 to $16.
The company has sold 81 ReWalk systems as of the beginning of August since becoming FDA approved in June.
ReWalk had revenue of $950,000 for the six months ended June 30, 2014, and booked $2 million in sales for the 12 months ended June 30, 2014.
The company has no plans of slowing down citing manufacturing relocation as a major contributor to lowering cost per unit.
Not bad for a company found merely 13 years ago, in 2001.